Potent immunomodulatory effects of the trifunctional antibody catumaxomab

Cancer Research

Volumn 73, Issue 15, 2013, Pages 4663-4673

  Goéré, Diane ^a,c   Flament, Caroline ^a,b   Rusakiewicz, Sylvie ^a   Poirier, Vichnou Colame ^a   Kepp, Oliver ^a,d   Martins, Isabelle ^a   Pesquet, Julien ^a   Eggermont, Alexander ^d   Elias, Dominique ^c   Chaput, Nathalie ^a,b,d   Zitvogel, Laurence ^a,b,d  

^a INSERM   (France)

^b Centre D'Investigation Clinique de Biothérapies Du Cancer CICBT   (France)

^c Institut Custave Roussy   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; B7 ANTIGEN; BEVACIZUMAB; CALRETICULIN; CARBOPLATIN; CATUMAXOMAB; CD16 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD69 ANTIGEN; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; HLA DR ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; OXALIPLATIN; PACLITAXEL; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; ASCITES CELL; ASCITES FLUID; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MALIGNANT ASCITES; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TUMOR CELL; UPREGULATION;

ADULT; AGED; ANTIBODIES, BISPECIFIC; ASCITES; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84881420516     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4460     Document Type: Article

References (41)

1. Sebastian M. Review of CatmAb in the treatment of malignant ascites. Cancer Manag Res 2010;2:283-6.
2. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004;35:122-8.
3. Spizzo G, Fong D,WurmM, Ensinger C, Obrist P, Hofer C, et al.EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol 2011;64:415-20.
4. Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H, et al. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEp- CAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 2004;25: 841-8.
5. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-52.
6. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6.
7. Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E, et al. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 2008;14:5849-55.
8. Gastl G, Spizzo G, Obrist P, Dünser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356: 1981-2.
9. Hirschhaeuser F, Walenta S, Mueller-Klieser W. Efficacy of CatmAb in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol Immunother 2010;59:1675-84.
10. Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117:435-43.
11. Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti- CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-905.
12. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010;127: 2209-21.
13. Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay- Oezcelik G, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol 2012;23:1979-85.
14. Jäger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody CatmAb (anti-EpCAM x anti-CD3). Cancer Res 2012;72:24-32.
15. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911.
16. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010;140:798-804.
17. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61.
18. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancerchemotherapy and radiotherapy. NatMed2007;13:1050-9.
19. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immuneresponses induced by chemotherapeutic agents in mice. Science 2011;334:1573-7.
20. Zitvogel L, Kroemer G. Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest 2009;119:2127-30.
21. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011;8: 151-60.
22. Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 2006; 203:2865-77.
23. Schmueck M, Fischer AM, Hammoud B, Brestrich G, Fuehrer H, Luu SH, et al. Preferential expansion of human virus-specific multifunctional central memory T cells by partial targeting of the IL-2 receptor signaling pathway: the key role of CD4 +T cells. J Immunol 2012;188: 5189-98.
24. Nemes E, Lugli E, Bertoncelli L, Nasi M, Pinti M, Manzini S, et al.CD4+ T-cell differentiation, regulatory T cells and gag-specific T lymphocytes are unaffected by CD4-guided treatment interruption and therapy resumption. AIDS 2011;25:1443-53.
25. Marshall NB, Swain SL. Cytotoxic CD4 T cells in antiviral immunity. J Biomed Biotechnol 2011;2011:954602.
26. Woopen H, Pietzner K, Darb-Esfahani S, Oskay-Oezcelik G, Sehouli J. Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature. Med Oncol 2012;29:3416-20.
27. Rüssel J, Stein A, Behrmann C, Hauptmann S, Krummenerl P, Schmoll HJ, et al. Inflammatory lesions of the peritoneummimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab. J Clin Oncol 2011;29:e644-6.
28. Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 2009;28:18.
29. OttMG, Marme F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, et al. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 2012;130:2195-203.
30. Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999;189:371-80.
31. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
32. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, et al. IL-10 elicits IFNg-dependent tumor immune surveillance. Cancer Cell 2011;20:781-96.
33. Emmerich J, Mumm JB, Chan IH, Laface D, Truong H, McClanahan T, et al. IL-10 directly activates and expands tumor-resident CD8+T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 2012;72:3570-81.
34. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010;2:63ra94.
35. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009;28: 578-90.
36. Hoves S, Sutton VR, Haynes NM, Hawkins ED, Fernandez Ruiz D, Baschuk N, et al. A critical role for granzymes in antigen crosspresentation through regulating phagocytosis of killed tumor cells. J Immunol 2011;187:1166-75.
37. Ahrens S, Zelenay S, Sancho D, Hanc P, Kjær S, Feest C, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity 2012;36: 635-45.
38. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009;8:3723-8.
39. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL- 1beta-dependent adaptive immunity against tumors. Nat Med 2009;15:1170-8.
40. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012;36:362-73.
41. Stagg J, Beavis PA, Divisekera U, Liu MC, Möller A, Darcy PK, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2012;72:2190-6.